This company has been marked as potentially delisted and may not be actively trading. NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medicis Pharmaceutical Stock (NYSE:MRX) Get Medicis Pharmaceutical alerts:Sign Up Key Stats Today's Range$32.54▼$33.3350-Day Range N/A52-Week Range$18.13▼$49.34Volume415,945 shsAverage Volume644,091 shsMarket Capitalization$2.25 billionP/E RatioN/ADividend Yield1.75%Price Target$43.71Consensus RatingModerate Buy Company Overview Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta). Read More Medicis Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreMRX MarketRank™: Medicis Pharmaceutical scored higher than 32% of companies evaluated by MarketBeat, and ranked 824th out of 945 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingMedicis Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialMedicis Pharmaceutical has a consensus price target of $43.71, representing about 36.7% upside from its current price of $31.98.Amount of Analyst CoverageMedicis Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Medicis Pharmaceutical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-0.34% Earnings GrowthEarnings for Medicis Pharmaceutical are expected to decrease by -0.34% in the coming year, from $2.94 to $2.93 per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MRX. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldMedicis Pharmaceutical pays a meaningful dividend of 1.44%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthMedicis Pharmaceutical does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 19.11% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.Read more about Medicis Pharmaceutical's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MRX. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 27 news articles for Medicis Pharmaceutical this week, compared to 1 article on an average week.Search Interest24 people have searched for MRX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Medicis Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.79% of the stock of Medicis Pharmaceutical is held by insiders.Read more about Medicis Pharmaceutical's insider trading history. Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRX Stock News HeadlinesMarex Group Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Marex Group plc - MRX4 hours ago | globenewswire.comMRX INVESTORS: Kirby McInerney LLP Reminds Marex Group PLC Investors of Important Deadline in Class Action LawsuitOctober 15 at 8:00 PM | businesswire.comREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today. | Paradigm Press (Ad)Deadline Approaching: Marex Group PLC (MRX) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. SmithOctober 15 at 4:08 PM | businesswire.comMRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marex GroupOctober 15 at 10:44 AM | prnewswire.comMarex announces share purchases by Directors and OfficersOctober 15 at 8:15 AM | globenewswire.comMarex Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MRXOctober 15 at 3:57 AM | prnewswire.comMRX Investors Have Opportunity to Lead Marex Group plc Securities Fraud Lawsuit with the Schall Law FirmOctober 15 at 3:55 AM | prnewswire.comSee More Headlines MRX Stock Analysis - Frequently Asked Questions How were Medicis Pharmaceutical's earnings last quarter? Medicis Pharmaceutical Corp (NYSE:MRX) posted its quarterly earnings results on Wednesday, August, 13th. The healthcare company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.09. Medicis Pharmaceutical's revenue was up 18.5% compared to the same quarter last year. When did Medicis Pharmaceutical IPO? Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering on Thursday, April 25th 2024. The company issued 15,384,615 shares at $19.00 per share. Who are Medicis Pharmaceutical's major shareholders? Medicis Pharmaceutical's top institutional shareholders include Farther Finance Advisors LLC. What other stocks do shareholders of Medicis Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicis Pharmaceutical investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/13/2025Record date for 9/11 Dividend8/26/2025Ex-Dividend for 9/11 Dividend8/26/2025Dividend Payable9/11/2025Today10/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Security & commodity brokers, dealers, exchanges & services Sub-IndustryN/A Current SymbolNYSE:MRX CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployees2,074Year FoundedN/APrice Target and Rating Average Price Target for Medicis Pharmaceutical$43.71 High Price Target$54.00 Low Price Target$34.00 Potential Upside/Downside+36.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.18 Current Ratio1.04 Quick Ratio1.08 Sales & Book Value Annual Sales$1.24 billion Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares70,290,000Free Float67,627,000Market Cap$2.25 billion OptionableOptionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NYSE:MRX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicis Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
